Literature DB >> 20683968

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites.

Brent A Neuschwander-Tetri1.   

Abstract

A significant body of evidence now forces us to rethink the causes of NASH. Once thought to be a disease caused by triglyceride accumulation in hepatocytes with subsequent oxidant stress and lipid peroxidation causing inflammation and fibrosis, new data from animal studies and a limited number of human studies now provide convincing evidence that triglyceride accumulation does not cause insulin resistance or cellular injury in the liver. The lipotoxic liver injury hypothesis for the pathogenesis of NASH suggests that we need to focus our therapeutic efforts on reducing the burden of fatty acids going to the liver or being synthesized in the liver. This can be accomplished by improving insulin sensitivity at the level of adipose tissue to prevent inappropriate peripheral lipolysis and by preventing unnecessary de novo lipogenesis in the liver. Excess carbohydrates are the major substrates for de novo lipogenesis, and thus, reducing carbohydrate consumption through dietary changes and increasing muscle glucose uptake through exercise remain important cornerstones of treatment and prevention of lipotoxic liver injury, a disease hitherto called NASH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683968     DOI: 10.1002/hep.23719

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  352 in total

1.  Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.

Authors:  Hussam Alamri; Nathan Heath Patterson; Ethan Yang; Pablo Zoroquiain; Anthoula Lazaris; Pierre Chaurand; Peter Metrakos
Journal:  Anal Bioanal Chem       Date:  2018-12-05       Impact factor: 4.142

2.  Estrogen receptor-α signaling maintains immunometabolic function in males and is obligatory for exercise-induced amelioration of nonalcoholic fatty liver.

Authors:  Nathan C Winn; Thomas J Jurrissen; Zachary I Grunewald; Rory P Cunningham; Makenzie L Woodford; Jill A Kanaley; Dennis B Lubahn; Camila Manrique-Acevedo; R Scott Rector; Victoria J Vieira-Potter; Jaume Padilla
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-12-04       Impact factor: 4.310

3.  Mixed Lineage Kinase 3 Mediates the Induction of CXCL10 by a STAT1-Dependent Mechanism During Hepatocyte Lipotoxicity.

Authors:  Kyoko Tomita; Ayano Kabashima; Brittany L Freeman; Steven F Bronk; Petra Hirsova; Samar H Ibrahim
Journal:  J Cell Biochem       Date:  2017-05-15       Impact factor: 4.429

4.  Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

Authors:  Kathleen E Corey; Naga Chalasani
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

Review 5.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

6.  Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats.

Authors:  Melissa A Linden; Justin A Fletcher; E Matthew Morris; Grace M Meers; Monica L Kearney; Jacqueline M Crissey; M Harold Laughlin; Frank W Booth; James R Sowers; Jamal A Ibdah; John P Thyfault; R Scott Rector
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-10       Impact factor: 4.310

Review 7.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

8.  Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a.

Authors:  Shuxia Wang; Kangxing Song; Roshni Srivastava; Chao Dong; Gwang-Woong Go; Na Li; Yasuko Iwakiri; Arya Mani
Journal:  FASEB J       Date:  2015-04-27       Impact factor: 5.191

9.  Scutellaria baicalensis regulates FFA metabolism to ameliorate NAFLD through the AMPK-mediated SREBP signaling pathway.

Authors:  Qian Chen; Mengyang Liu; Haiyang Yu; Jian Li; Sijian Wang; Yi Zhang; Feng Qiu; Tao Wang
Journal:  J Nat Med       Date:  2018-03-14       Impact factor: 2.343

10.  5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.

Authors:  Leyuan Xu; Jin Koung Kim; Qianming Bai; Xin Zhang; Genta Kakiyama; Hae-Ki Min; Arun J Sanyal; William M Pandak; Shunlin Ren
Journal:  Mol Pharmacol       Date:  2012-12-20       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.